Accessibility Menu
Evogene logo

Evogene

(NASDAQ) EVGN

Current Price$0.59
Market Cap$7.49M
Since IPO (2008)-95%
5 Year-98%
1 Year-44%
1 Month-22%

Evogene Financials at a Glance

Market Cap

$7.49M

Revenue (TTM)

$1.84M

Net Income (TTM)

-$11.77M

EPS (TTM)

-$1.38

P/E Ratio

-0.45

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$0.59

Volume

390,452.232

Open

$0.58

Previous Close

$0.62

Daily Range

$0.58 - $0.64

52-Week Range

$0.52 - $2.42

Estimated Earnings Date

Aug 20, 2026

EVGN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evogene

Industry

Biotechnology

Employees

52

CEO

Ofer Haviv, CPA

Headquarters

Rehovot, 7414002, IL

EVGN Financials

Key Financial Metrics (TTM)

Gross Margin

31%

Operating Margin

-8%

Net Income Margin

-6%

Return on Equity

-655%

Return on Capital

-1%

Return on Assets

-65%

Earnings Yield

-2.22%

Dividend Yield

0.00%

Payout Ratio

-1.65%

Stock Overview

Market Cap

$7.49M

Shares Outstanding

12.10M

Volume

390.45K

Avg. Volume

515.05K

Financials (TTM)

Gross Profit

-$241.00K

Operating Income

-$14.03M

EBITDA

-$12.20M

Operating Cash Flow

-$13.50M

Capital Expenditure

-$135.00K

Free Cash Flow

-$13.64M

Cash & ST Invst.

$12.99M

Total Debt

$2.20M

Evogene Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$334.00K

-86.3%

Gross Profit

$204.00K

-75.4%

Gross Margin

61.08%

N/A

Market Cap

$7.49M

N/A

Market Cap/Employee

$64.04K

N/A

Employees

117

N/A

Net Income

-$5.87M

-126.9%

EBITDA

-$1.82M

+6.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$11.06M

+455.0%

Accounts Receivable

$286.00K

-91.3%

Inventory

$175.00K

-91.9%

Long Term Debt

$1.38M

-28.4%

Short Term Debt

$654.00K

-94.1%

Return on Assets

-65.36%

N/A

Return on Invested Capital

-1.10%

N/A

Free Cash Flow

-$2.96M

+44.3%

Operating Cash Flow

-$2.95M

+43.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLRBCellectar Biosciences, Inc.
$2.59-5.82%
BOLTBolt Biotherapeutics, Inc.
$4.56-3.80%
IMNNImunon, Inc.
$2.06-1.90%
COCPCocrystal Pharma, Inc.
$0.96-8.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$14.38-0.13%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.05-0.14%
KEELKeel Infrastructure
$5.13-0.13%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.19+0.14%

Questions About EVGN

What is the current price of Evogene?

Evogene is trading at $0.62 per share.

What is the 52-week range for Evogene?

Over the past 52 weeks, Evogene has traded between $0.52 and $2.42.

How much debt does Evogene have?

As of the most recent reporting period, Evogene reported total debt of $2.03M.

How much cash does Evogene have on hand?

Evogene reported $8.54M in cash and cash equivalents in its most recent financial results.

What is Evogene’s dividend yield?

Evogene does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.